Bluejay Diagnostics, Inc. (BJDX): Submission of Matters to a Vote of Security Holders
Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split ACTON, Mass., October 30, 2026 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient di
How this was made
The 30-second read
Why it matters
The reverse split will adjust share count and may improve per‑share price perception, but does not change the company's cash position or product pipeline.
Market read
Primary corporate action for a micro‑cap; limited broader market impact but relevant for shareholders and short‑term traders.
What to watch
The split does not address the company's lack of FDA clearance for its Symphony™ system, which remains the primary risk.
Background
Bluejay Diagnostics is a Nasdaq‑listed micro‑cap focused on near‑patient diagnostic platforms, currently awaiting FDA clearance for its lead product.
Ticker impact
Bluejay Diagnostics announced a 1‑for‑4 reverse stock split effective Nov 3, 2026, reducing shares outstanding and adjusting warrants.
potential pressure as investors reassess valuation post‑split
Reverse splits often trigger trading activity and can lead to temporary price swings, but no fundamental change to the business.
Market effects
Minimal; the diagnostic sector is not broadly impacted by a single micro‑cap split.
Limited to U.S. small‑cap investors and Nasdaq Capital Market participants.
Low; no global macro or sector ripple effects.
Counterpoint
Some traders may view the split as a chance to buy at a lower share price if they believe the business fundamentals remain intact.
Key entities
- companyBluejay Diagnostics, Inc.
Medical diagnostics firm announcing the reverse split.
- service_providerContinental Stock Transfer & Trust Company
Acting as exchange agent for the split.

